Methotrexate Drugs Market Size & Share, by Dosage Form (>10 mg, >15 mg/ml, 17.5 mg/ml - 25 mg/ml); Disease Type (Cancer, Autoimmune Diseases, Ectopic Pregnancy); Drug Type (Branded, Generics); Route of Administration (Injectable, Oral); End-user (Hospitals, Specialty Clinics, Home Healthcare) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2031

  • Report ID: 2738
  • Published Date: Jul 27, 2023
  • Report Format: PDF, PPT

Global Methotrexate Drug Market TOC

 

  1. Market Definition
    1. Definition
    2. Market Segmentation
    3. Product Overview
  2. Assumptions and Acronyms
  3. Research Methodology
    1. Research Process
    2. Primary Research
      1. Manufacturers
      2. Suppliers/Distributors
      3. End-Users
    3. Secondary Research
    4. Market Size Estimation
  4. Analyst Review
  5. Executive Summary – Global Methotrexate Drug Market
  6. Market Dynamics
    1. Growth Drivers
    2. Restraints
    3. Market Trends
    4. Opportunities
  7. Regulatory and Standards Landscape
    1. FDA
    2. WHO
    3. Others
  8. Industry Risk Analysis
  9. World Economic Outlook: Challenges for Global Recovery and its Impact on Global Methotrexate Drug Market
  10. Impact of COVID-19 on the Global Methotrexate Drug Market
  11. Epidemiology Analysis of Cancer and Rheumatoid Arthritis
  12. End-user analysis
  13. Industry Supply Chain Analysis
  14. Competitive Landscape
    1. Company Market Share Analysis
    2. Company Profiles
      1. Pfizer Inc.
      2. Azurity Pharmaceuticals, Inc.
      3. Cumberland Pharmaceuticals Inc.
      4. Teva Pharmaceuticals USA, Inc.
      5. Amneal Pharmaceuticals LLC
      6. Sun Pharmaceutical Industries Ltd.
      7. Aurobindo Pharma Limited,
      8. Sandoz Inc
      9. Hikma Pharmaceuticals PLC
      10. Eisai Co., Ltd.
      11. Other prominent players
  15. Global Methotrexate Drug Market 2021-2031
    1. Market Overview
    2. By Value (USD Million)
      1. By Type  
        1. >10 mg, 2021-2031F (USD Million)
        2. >15 mg/ml, 2021-2031F (USD Million)
        3. 17.5 mg/ml – 25 mg/ml, 2021-2031F (USD Million)
        4. Others, 2021-2031F (USD Million)
      2. By Disease Type
        1. Cancer, 2021-2031F (USD Million)
          1. Breast Cancer, 2021-2031F (USD Million)
          2. Leukemia, 2021-2031F (USD Million)
          3. Lung Cancer, 2021-2031F (USD Million)
          4. Lymphoma, 2021-2031F (USD Million)
          5. Gestational Trophoblastic Disease, 2021-2031F (USD Million)
          6. Osteosarcoma, 2021-2031F (USD Million)
        2. Autoimmune Diseases, 2021-2031F (USD Million)
          1. Psoriasis, 2021-2031F (USD Million)
          2. Rheumatoid Arthritis, 2021-2031F (USD Million)
          3. Crohn's Disease, 2021-2031F (USD Million)
          4. Others, 2021-2031F (USD Million)
        3. Ectopic Pregnancy, 2021-2031F (USD Million)
        4. Others, 2021-2031F (USD Million)
      3. By Drug Type
        1. Branded, 2021-2031F (USD Million)
        2. Generics, 2021-2031F (USD Million)
      4. By Route Of Administration
        1. Injectable, 2021-2031F (USD Million)
        2. Oral, 2021-2031F (USD Million)
      5. By End User
        1. Hospitals, 2021-2031F (USD Million)
        2. Specialty Clinics, 2021-2031F (USD Million)
        3. Home Healthcare, 2021-2031F (USD Million)
        4. Others, 2021-2031F (USD Million)
      6. By Region
        1. North America, 2021-2031F (USD Million)
        2. Europe, 2021-2031F (USD Million)
        3. Asia Pacific, 2021-2031F (USD Million))
        4. Latin America, 2021-2031F (USD Million)
        5. Middle East & Africa, 2021-2031F (USD Million)
  16. North America Methotrexate Drug Market 2021-2031
    1.  Market Overview
    2. By Value (USD Million)
      1. By Type 
        1. >10 mg, 2021-2031F (USD Million)
        2. >15 mg/ml, 2021-2031F (USD Million)
        3. 17.5 mg/ml – 25 mg/ml, 2021-2031F (USD Million)
        4. Others, 2021-2031F (USD Million)
      2. By Disease Type
        1. Cancer, 2021-2031F (USD Million)
          1. Breast Cancer, 2021-2031F (USD Million)
          2. Leukemia, 2021-2031F (USD Million)
          3. Lung Cancer, 2021-2031F (USD Million)
          4. Lymphoma, 2021-2031F (USD Million)
          5. Gestational Trophoblastic Disease, 2021-2031F (USD Million)
          6. Osteosarcoma, 2021-2031F (USD Million)
        2. Autoimmune Diseases, 2021-2031F (USD Million)
          1. Psoriasis, 2021-2031F (USD Million)
          2. Rheumatoid Arthritis, 2021-2031F (USD Million)
          3. Crohn's Disease, 2021-2031F (USD Million)
          4. Others, 2021-2031F (USD Million)
        3. Ectopic Pregnancy, 2021-2031F (USD Million)
        4. Others, 2021-2031F (USD Million)
      3. By Drug Type
        1. Branded, 2021-2031F (USD Million)
        2. Generics, 2021-2031F (USD Million)
      4. By Route Of Administration
        1. Injectable, 2021-2031F (USD Million)
        2. Oral, 2021-2031F (USD Million)
      5. By End User
        1. Hospitals, 2021-2031F (USD Million)
        2. Specialty Clinics, 2021-2031F (USD Million)
        3. Home Healthcare, 2021-2031F (USD Million)
        4. Others, 2021-2031F (USD Million)
      6. By Country
        1. United States, 2021-2031F (USD Million)
        2. Canada, 2021-2031F (USD Million)
  17. Europe Methotrexate Drug Market 2021-2031
    1. Market Overview
    2. By Value (USD Million)
      1. By Type  
      2. By Disease Type
      3. By Drug Type
      4. By Route Of Administration
      5. By End User
      6. By Country
        1. United Kingdom, 2021-2031F (USD Million)
        2. Germany, 2021-2031F (USD Million)
        3. France, 2021-2031F (USD Million)
        4. Italy, 2021-2031F (USD Million)
        5. Spain, 2021-2031F (USD Million)
        6. Russia, 2021-2031F (USD Million)
        7. Netherlands, 2021-2031F (USD Million)
        8. Rest of Europe, 2021-2031F (USD Million)
  18. Asia Pacific Methotrexate Drug Market 2021-2031
    1.  Market Overview
    2. By Value (USD Million)
      1. By Type  
      2. By Disease Type
      3. By Drug Type
      4. By Route Of Administration
      5. By End User
      6. By Country
        1. China, 2021-2031F (USD Million)
        2. India, 2021-2031F (USD Million)
        3. Japan, 2021-2031F (USD Million)
        4. South Korea, 2021-2031F (USD Million)
        5. Singapore, 2021-2031F (USD Million)
        6. Australia, 2021-2031F (USD Million)
        7. Rest of Asia Pacific, 2021-2031F (USD Million)
  19. Latin America Methotrexate Drug Market 2021-2031
    1. Market Overview
    2. By Value (USD Million)
      1. By Type 
      2. By Disease Type
      3. By Drug Type
      4. By Route Of Administration
      5. By End User
      6. By Country
        1. Brazil, 2021-2031F (USD Million)
        2. Mexico, 2021-2031F (USD Million)
        3. Argentina, 2021-2031F (USD Million)
        4. Rest of Latin America, 2021-2031F (USD Million)
  20. Middle East & Africa Methotrexate Drug Market 2021-2031
    1. Market Overview
    2. By Value (USD Million)
      1. By Type 
      2. By Disease Type
      3. By Drug Type
      4. By Route Of Administration
      5. By End User
      6. By Country
        1. Israel, 2021-2031F (USD Million)
        2. GCC, 2021-2031F (USD Million)
        3. South Africa, 2021-2031F (USD Million)
        4. Rest of Middle East & Africa, 2021-2031F (USD Million)

Companies Dominating the Methotrexate Drugs Market

top-features-companies
    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Azurity Pharmaceuticals, Inc.
    • Cumberland Pharmaceuticals Inc.
    • Teva Pharmaceuticals USA, Inc.
    • Amneal Pharmaceuticals LLC
    • Sun Pharmaceutical Industries Ltd.
    • Aurobindo Pharma Limited,
    • Sandoz Inc
    • Hikma Pharmaceuticals PLC
    • Eisai Co., Ltd.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Eisai Co., Ltd and nippon medac Co., Ltd. announced a manufacturing and marketing approval of Metoject Subcutaneous Injection (Methotrexate) from the Japanese Ministry of Health, Labour and Welfare for the treatment of rheumatoid arthritis.
  • Cumberland Pharmaceuticals Inc. announced the launch of RediTrex (methotrexate) injection which is designed for dosing accuracy for the subcutaneous administration of methotrexate in patients with arthritis and psoriasis.

     


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 2738
  • Published Date: Jul 27, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The surge in the prevalence of rheumatoid arthritis and the increasing prevalence of cancer are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 2.9% over the forecast period, i.e., 2022 – 2031.

The major players in the market are Pfizer Inc., Azurity Pharmaceuticals, Inc., Cumberland Pharmaceuticals Inc., Inc, Teva Pharmaceuticals USA, Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, and Others

The cancer segment is anticipated to garner the largest market size by the end of 2031 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2031 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying